Pier 70 Ventures
VC Fund
Seattle, United States
Pier 70 Ventures is a VC fund in Seattle focused on Health Care and Medical. Pier 70 Ventures fund disruptive technologies with the potential to shake up the status quo in healthcare.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Pier 70 Ventures invests in
Stages Pier 70 Ventures invests in
Countries Pier 70 Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $2.3M–$5.5M
- Series B
- $10M–$16M
Investment Focus
Industry
- Health Care 5 (56%)
- Medical 4 (44%)
- Biotechnology 2 (22%)
- Medical Device 2 (22%)
- SaaS 1 (11%)
Stage
- Seed 3 (33%)
- Series B 2 (22%)
- Series A 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Preetha Ram
Senior Managing Director & General Partner, INpact Fund
|
Senior Managing Director & General Partner, INpact Fund | Total investments: 2 | Find email | |
Shaun Hawkins
Managing Partner
|
Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DermaSensor
|
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $16M / Series B / Oct 02, 2025 | |
Flyte
|
Flyte is a femtech company that specializes in developing solutions to cure bladder leaks. It offers an in-home intravaginal device that both treats stress urinary incontinence and provides biofeedback to help patients strengthen pelvic floor muscles at home. | $2.3M / Seed / Apr 22, 2024 | |
PrīmSphera
|
Vital View Technologies is a company that is developing sensor technology that generates new insights to solve real-world problems. It's making a paradigm shift in product development, design, and commercialization. | $5.5M / Seed / Dec 05, 2023 | |
KayoThera
|
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $5.2M / Series A / Jul 19, 2023 | |
Community
|
Community is a new social engagement platform that makes two-way communication between influencers and their followers simple, effective, and scalable. It connects businesses, brands, governmental and public personalities, creators, singers, celebrities, and others to their consumers at scale via a unique 10-digit phone number. | $25M / Venture - Series Unknown / Apr 24, 2023 | |
ZeroCarb LYFE
|
ZeroCarbLYFE is a food tech company with the mission to bring joy into healthy food. We invented multiple high proteins, and low/no carb foods that taste as good as or better than carb-loaded alternatives. | $3.2M / Mar 31, 2023 | |
|
ZeroCarb LYFE
|
ZeroCarbLYFE is a food tech company with the mission to bring joy into healthy food. We invented multiple high proteins, and low/no carb foods that taste as good as or better than carb-loaded alternatives. | $3.2M / Mar 31, 2023 | |
|
ZeroCarb LYFE
|
ZeroCarbLYFE is a food tech company with the mission to bring joy into healthy food. We invented multiple high proteins, and low/no carb foods that taste as good as or better than carb-loaded alternatives. | $3.2M / Seed / Mar 17, 2023 | |
DocSpera
|
DocSpera is an integrated surgical coordination platform to help manage synchronization across multiple sites and teams, drive improved workflow efficiencies, and deliver better patient care. DocSpera’s proprietary platform automates pre-surgical coordination. It offers real-time, compliant, secure case and image synchronization among all caredelivery stakeholders: Surgeon, Care Team, and Device Supplier, using EHR data. DocSpera is part of Compliant Innovations Inc and headquartered in Sunnyvale, CA. | $10M / Series B / Sep 27, 2022 |
Co-Investors
Elevate Ventures
4 deals together
Render capital
3 deals together
Sixty8 Capital
3 deals together
32 Ventures
1 deal together
Accelerator Life Science Partners
1 deal together
Backstage Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Pier 70 Ventures invest in?
Pier 70 Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pier 70 Ventures's check size?
Pier 70 Ventures typically joins rounds of $2.3M–$5.5M at Seed and $10M–$16M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pier 70 Ventures participates in.
How do I contact Pier 70 Ventures?
Public channels for Pier 70 Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pier 70 Ventures?
The team at Pier 70 Ventures includes Preetha Ram (Senior Managing Director & General Partner, INpact Fund) and Shaun Hawkins (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
